The new investment brings the total investment made by the two investors in Synoste to €10m ($11.5m). Evonik Venture Capital, High-Tech Gründerfonds, Innovestor Ventures, and Mectalent are some of the other investors in the company.
Synoste focuses on the development of bone lengthening and deformity correction solutions. The company plans to use the funds raised to initiate clinical investigations and for the development of clinical solutions.
All the companies involved in the transaction are based in Finland.
Collplant has entered an agreement with United Therapeutics to develop 3D-bioprinted solid-organ scaffolds for lung transplants in humans.
United Therapeutics will secure an exclusive permit to manufacture and commercialise Collplant’s rhCollagen-based BioInk technology. The licence could be further expanded for three other organs.
Collplant will receive an upfront payment of $5m and up to $15m as operational and milestone payments from United Therapeutics. The company is also eligible for an additional $9m as option exercise payments and up to $15m as development milestone payments.
Based in Israel, Collplant is a regenerative medicine company focused on the development of 3D-bioprinted tissues and organs, while United Therapeutics is a biotechnology company based in the US.
The robotic system supports patients suffering from neurological diseases to regain limb mobility from the comfort of their home.
Based in Canada, Bionik Laboratories is a robotics company focused on mobility solutions, while Clinique Les Trois Soleils is a rehabilitation centre based in France.
Siemens Healthineers has collaborated with Healthy.io to enhance the monitoring of kidney disease by at-home urine testing.
Siemens’ urinalysis reagents and Healthy.io’s smartphone-based urinalysis system will be integrated to improve the accuracy of test results, which will be delivered to the patient’s clinician via an app.
Based in Germany, Siemens Healthineers is a medical technology company, while Healthy.io is an Israel-based start-up company focused on the development of urinalysis analyser.
Valeda™ is used as a treatment for dry age-related macular degeneration (AMD).
LumiThera will receive the right to commercialise the system across Europe.
Based in the US, LumiThera develops photobiomodulation treatment for patients with dry-AMD, while Optos is a Japan-based ultra-widefield retinal imaging company and a subsidiary of Nikon Corporation.